Environment and Pharmaceutical Impurities a Global Concern

Akash B.Avhad[1], Bhushan G.Sanap[2], Veneshwar D.Nagare[3], Bhushan C.Thore[4], Sonam R.Sanap[5]
Department of Quality Assurance Techniques, KVN'S NIPOER, Nashik, MS, India
Department of Quality Assurance Techniques, KVN'S NIOPER, Nashik

***Abstract*- Pharmaceuticals and cosmetic products are an essential component of contemporary healthcare systems and are dispersed into the environment in a variety of ways. Their presence in soil and the aquatic environment offers a number of eco-toxicological issues due to their innate biological activity. Numerous international organizations, including the WHO and EPA, have acknowledged that antibiotic contamination of soil and water sources is contributing to the emergence of microbial resistance to antibiotics. The pharmaceutical industry and healthcare professionals need to follow green and sustainable pharmaceutical practices, and better remediation/bioremediation techniques are among the effective actions that need to be implemented in this regard. This chapter describes the many predicted pathways of pharmaceutical exposure to the environment, as well as the harmful outcomes, destiny, and degradation in aquatic systems.**

Key words: Pharmaceuticals, environmental, impurities, side products, elimination.

INTRODUCTION

Modern society uses pharmaceutical substances for a variety of good reasons, but at the same time, the pharmaceutical industry releases extremely harmful toxins into the environment either directly or after chemical alterations. [1] Additionally, pharmaceutical substances could enter the environment through numerous channels, including runoff, seepage from landfills, sewer systems, and discharge of treated wastewater the feces of animals, etc. Despite the fact that there are many physical and biological processes in aquatic trace amounts of human and pharmaceutical substances may decrease due to environmental changes. Different types of water contain veterinary medicinal chemicals and their metabolites present. Bodies including drinking water supplies, groundwater, and surface water.[2]

The revelation of waste pharmaceuticals in the environment poses threats to humans, aquatic life, and wildlife around the world and is developing into a significant issue. Equally for the pharmaceutical industry's regulators. Significant progress on this topic simply isn't possible. given the existing state of knowledge on environmental transit, fate, and impacts, this is only about pharmaceuticals. Consideration must be given to potential pharmacological adverse effects that could worsen. Risk assessment of pharmaceutical compounds entails the detection of the same receptors, inherent dangers at every level and a projection of the risks brought on by these risks.[3]

Classification of India's biomedical waste regulations from 1998 [4-6]

What is biomedical waste?
The trash produced during diagnostic or vaccination of people or animals, in scientific experiments, in the creation, biological product testing, or biological analysis

Ownership by the operator
The manager of any hospital or facility that houses animals make sure BMWs are managed so there is no negative impact on Environment and human health.

Endorsed authority
State and territorial State Pollution Control Boards (SPCBs) and Pollution Control Committees, respectively, are in charge of approving and enforcing the Biomedical Waste Rules' requirements.[7]

Common locations for disposal and burning
The operators of such facilities must abide by the Biomedical Waste Rules, and local public entities must provide common disposal/incineration sites.[8]

Risks in the pharmaceutical industries

Installations for formulation and production. handling and storing dangerous chemicals in facilities like warehouses, the Lord's, and tanks in docks, fuel depots, and ports.[9]

Transportation (road, rail, air, water, pipelines) (road, rail, air, water, pipelines).

Pollutant emissions include the following: sulphur dioxide (SO2), volatile organic compounds (VOCs), particulate matter of 10 millimetres or smaller (PM10), total suspended particulate matter (SPM), carbon monoxide (CO), and nitrogen dioxide (NO2) (VOCs). The most prevalent VOCs are acetonitrile, dichloromethane, toluene, ethylene glycol, and N, N-dimethyl formamide. Effluents, especially those that are poisonous and difficult to biodegrade. [10-12]

PHARMACEUTICALS IN ENVIRONMENT

The effluent emissions could reach lakes, rivers, oceans, streams, or other bodies of water immediately. Releases brought on by runoff, such as storm water runoff, may also pose a risk. Water and soil are contaminated by hundreds of active com pounds that are employed in human and/or animal tre atments, as well as by their metabolites and degradati on products. Some of these medications are persistent , while others, known as pseudoPersistent medication s, are constantly present in the environment due to th eir frequent and extensive release. Pharmaceuticals c ontain a wide range of side effects, some of which are endocrine disruptors (such as synthetic hormones) an d others of which are intended to kill microorganisms (eg. antibiotics). [13-16]

Pharmaceuticals in rivers can endanger aquatic life and sources of drinking water.

In heavily polluted rivers (and also in groundwaters), levels can range from nanograms per litre (ng/L) (or parts per trillion 1012) to milligrammes per litre (mg/L) (or parts per million 106). Pharmaceuticals, howev er, are often more expensive in the EU. Almost everyone has taken medications that were either purchased over the counter in a drugstore or were prescribed by a doctor. In the EU, medications are presently consumed in enormous amounts. At retail pricing in 2007, the market for prescription and over-the-counter pharmaceuticals for human use in the EU was estimated to be worth approximately €214 billion (£169.7 billion), up from €48 billion (£38 billion) in 1990. [17] As the world's population ages, the trend of rising per capita consumption is expected to continue [18]. The quality of life we enjoy is frequently greatly improved by medications, yet little is known about the long-term effects these drugs' residues will have on both humans and wildlife.

There are still many knowledge gaps regarding how pharmaceuticals affect the diverse range of organisms in the environment, despite several research projects that have raised some concerns. This is especially true because the potential effects cannot always be predicted from the therapeutic effects on humans or from tests on a few species. Along with this issue, there is the challenge of figuring out whether the "cocktail effect," or the simultaneous exposure to low levels of numerous such chemicals and other environmental pollutants like pesticides, may have negative effects.[19-20]

Antibiotics (for infections), anti-cancer medications (for cancer), antidepressants (for depression), anti-parasitics (for parasites), NSAIDs (nonsteroidal anti-inflammatory drugs for reducing inflammation to ease joint pain and stiffness), betablockers (for hypertension and heart problems), lipid regulators, and others are among the pharmaceutical products raising concern due to their potential effects on wildlife. The effects of our current reliance on medications on the environment are the main subject of this briefing. The necessity to safeguard animals is particularly highlighted, yet because so many rivers and ground waters are also used for human use.[21]

ROUTES TO THE ENVIRONMENT

In general, between 30 and 90% of the oral dose is eliminated as active substance in the urine or faeces of both animals and people. This indicates that a sizeable part of the original drug can be excreted intact. This indicates that major pathways for drugs to enter the environment include hospital and municipal sewage works emissions. In fact, when it comes to human pharmaceutical pollution in the EU, routine usage and improper disposal of medications down the toilet are more likely to cause issues than discharges from manufacturing facilities. In contrast, very high amounts of pharmaceutical residues have been found

downstream of some production sites in underdeveloped nations like India.[22]

Aquaculture and extensive animal husbandry can cause large environmental discharges of pharmaceuticals when it comes to veterinary medications. Particularly animal medications can contaminate land through the use of manure and slurries. In a similar vein, some human drugs can also enter the environment by the usage of sewage sludge on agricultural land. For instance, it has been demonstrated that a number of medications created from sewage sludge can spread to crops likewise, antibiotics have been discovered in food plants (lettuce, corn, and potato) planted with animal manure.[23]

However, for those drug residues that do wind up in the soil, little is known about their destination, behaviour, and in particular, the effects of these compounds on soil microbes. Composting does have a tendency to diminish the levels of these medicines. Sewage sludge landfills may also create leachate that contains a considerable amount of medicines.[24] However, the three main ways that human medications contaminate waterways widely are as follows:

1. As a result of improperly disposing of unwanted medications into the toilet or drain (and then via STWs).
2. As a result of the medication being taken, either it or a metabolite excreted and then released by a STWs, or from STWs after dermal applications are washed off the skin during a bath.
3. From manufacturing facilities for pharmaceuticals or healthcare institutions, either directly or through direct discharges from wastewater treatment plants (WWTPs).

REGULATION OF PHARMACEUTICALS AS WATER POLLUTANTS

Directive 2000/60/EC of the European Parliament of the Council establishing a framework for Community action in the field of water policy (the Water Framework Directive (WFD)), as amended by its daughter directives, the Environmental Quality Standards Directive (EQSD) (2008/105/EC) and the Priority Substances in Water Directive (2013/39/EC) [25-17]

Pharmaceuticals in water have received little attention from European regulators thus far. To address chemical water contamination, the original Water Structure Directive (WFD) offers a framework. In order to priorities substances for action based on risk to or via the aquatic environment, the Environmental Quality Standards Directive (EQSD) alters the Water Framework Directive (WFD). 'Priority compounds' must be monitored in water at regular intervals and gradually removed from sediments and biota. There are currently 45 "previous compounds" listed in Annex X of the WFD, as updated by the EQSD in 2013, none of which are active medicinal ingredients.[28]

A proposal from the European Parliament to assess four medications with the possibility of putting them on the priority substance list was put off for a while. Amidotrizoate, carbamazepine, lopamidol, and diclofenac were those substances, however, as will be noted below, the last has at least been placed on the "watch list". Three prescription drugs were suggested by the Commission to be included to the list of "priority substances" in 2012. These included diclofenac, 17-estradiol (endogenous oestrogen used in hormone replacement therapy), and 17-ethinyl estradiol (used in the contraceptive pill) (a painkiller). after significant industry pressure.[29]

This was not agreed upon, and as a result of the compromise made during political negotiations, these 3 drugs were added to the first "watch list," which was created to collect monitoring data to support future reviews of the priority list and "for the specific purpose of facilitating the determination of appropriate measures to address the risk posed by these substances." The "watch list" system was required by Directive 2008/105/EC (EQSD) in order to provide high-quality monitoring data on potentially harmful compounds in the aquatic environment to facilitate future prioritisation. The compounds that are being targeted include those for which there aren't enough or poor-quality monitoring data to determine the risk posed across the EU. In addition to diclofenac, 17-estradiol, and 17-ethinyl estradiol, which have already been approved on the "watch list," a report from the EU Joint Research Centre (JRC) suggested include an additional seven drugs. Erythromycin, an antibiotic, and trichlorfon, a pesticide that is still used in veterinary medicine despite being banned as a pesticide, were two of the additional drugs it suggested Every four years, the priority list is reviewed, and as a result, compounds on the "watch list" that have a

confirmed considerable danger at the EU level may be added in the upcoming version.[30]
"Priority hazardous substances" refer to compounds for which Member States should take the appropriate steps to stop or gradually reduce emissions, discharges, and losses, whilst "priority substances" still need to have their levels gradually decreased. [31] This would require a significant increase in the level of care at some STWs in EU Member States, including the UK, for the contraceptive pill and other pollutants. Such investment is essential since the cumulative exposure to hormone-disrupting drugs in some rivers endangers fish and perhaps other species.
The required changes at STWs must be put into place if wildlife is to be protected and the advantages of contemporary medicine are to be realised.
However, advancing STWs will call for rapid research and the creation of new technologies. Water policy priority compounds are governed under Directive 2013/39/EU. The European Commission is given instructions in this Directive to further investigate the issue of water pollutants, and in particular to develop solutions to deal with the issue of pharmaceuticals in the environment.[32]

Drinking water standards
According to EU law, Member States must take the steps necessary to protect drinking water from contaminants, with a focus on the precautionary principle, to ensure that water intended for human use is free from pollutants in quantities that pose a possible threat to human health. However, monitoring the amounts of drugs in drinking water is not a necessity under EU law.[33]

Pharmaceuticals as contaminants of the soil
The issue of pharmaceutical items contaminating soil is not addressed at the EU level, and the majority of national regulations in Member States do not address this particular issue either. There is no requirement to monitor or regulate pharmaceutical residues in sewage sludge, despite the fact that UK law relates to heavy metals in sewage sludge applied to land However, all 7 medicines that were searched for in the sewage sludge from UK STWs were discovered to be present. Ibuprofen (0.27), propranolol (0.14), erythromycin (0.06), ofloxacin (0.22), oxytetracycline (7.63), and fluoxetine were six substances that were monitored in sludge from 28 STWs and discovered to be present at the mean amounts in mg/kg dry weight stated in parenthesis (o.13).[34]

Research Tasks
Additionally, there are EU research projects examining the environmental impacts of many of the older medications that were available on the market before an ERA was required. For instance, the Innovative Medicines Initiative, a joint initiative of the European Union and the pharmaceutical industry association (EFPIA), is working on a project called Ecorisk Prediction that aims to create a science-based methodology to support ERA by using information from preclinical and clinical studies as well as information about the mode of action to forecast how drugs will affect wildlife. It intends to resolve regulatory and public concerns about outdated pharmaceutical goods and to give the many unassessed medications top priority for a future assessment program.[35]

PHARMACEUTICALS IN THE ENVIRONMENT

Numerous substances have been detected in rivers, many of which have been found at low concentrations. The paper "Global occurrence of pharmaceuticals in the environment" contains the most thorough examination of the current level of knowledge regarding environmental pollution by medicines globally. While the full publication of this work won't likely be finished until the middle of 2015 (see IWW & Adelphi), it was done for the German Environment Agency (UBA) in order to support SAICM deliberations. The research examined consumption data and anticipated changes in each of the five United Nations (UN) regions while compiling measured environmental concentrations of human and veterinary medications reported there. on the environmental effects of pharmaceutical emissions. On the global significance of drugs in the environment, a database with numerous maps has been created . [36] According to this global study, 631 medicines—of which 127 are transformations products—were discovered to be above their detection thresholds out of 713 pharmaceuticals that were searched for in the environment (IWW, 2014). Pharmaceuticals have been found in the environment in 71 different nations. Surface samples contained sixteen pharmaceutically derived compounds.

In each of the UN regional groups, water can be surface water, groundwater, or drinking water. Diclofenac (for pain and inflammation), carbamazepine (for epilepsy), ibuprofen (for pain and inflammation), sulphamethazole (for an antibiotic), naproxen (for pain and inflammation), trimethoprim (for an antibiotic), paracetamol (for pain), clofibric acid (from the lipid-lowering medication), ciprofloxacin (from an antibiotic), ofloxacin (from an antibiotic), nor (IWW, 2014).

Diclofenac has undergone the greatest monitoring of these and has been found in water in about 50 different nations.[37]

In the end, a lot of medications will be shipped to aquatic environments. For instance, it has been reported that various medications have been found along the Baltic Sea coast off Germany. There are several of these, including 17-ethinyl estradiol, clofibric acid, ibuprofen, carbamazepine, gemfibrozil, diclofenac, bezafibrate, naproxen, and propyphenazone. The Swedish Medical Products Agency is currently leading a strategy to establish the Baltic Sea Region as a leader in pharmaceutical sustainable development. When analysing the outcomes of various targeted monitoring activities, [38] it is important to keep in mind that only a small number of the thousands of manufactured pharmaceuticals have analytical detection methods, and that these methods are not yet standardised globally. As a result, detection limits may differ. Despite the fact that drugs have also been discovered in soil and manure.

CONCLUSION

The current system of regulations for their discharge is unable to manage the untreated or partially treated pharmaceutical effluents, which are currently being released into the environment in extraordinarily large quantities on a regular basis. Ecosystems, biota, and people are all being affected by drug use. Thorough safety and toxicological research must be conducted to fully understand the side effects on human, aquatic, and animal health. Sincere efforts are needed to lessen the issue, as well as some suitable rules to track or manage them. The most frequently used pharmaceutical substances in drinking water sources must be analyzed as part of the water quality regulations that are enforced in India. Moreover, wastewater treatment plants of pharmaceutical industrial units must widely implement the most recent corrective methods.

REFERENCE

[1] Nessel, R.J., Wallace, D.H., Wehner, T.A., Tait, W.E., Gomez, L., 1989. Environmental fate of ivermectin in a cattle feedlot. Chemosphere 18, 1531–1541.

[2] NGWA, 2000. Emerging issues conference - pharmaceuticals - endocrine disrupting chemicals - pesticides - arsenic and radon. Emerging Issues Conference, Minneapolis, Minnesota, National Ground Water Association, 7–8 June (7–8 June).

[3] Nicholson, W.A., 1967. Collection of unwanted drugs from private homes. Br. Med. J. 3, 730–731.

[4] Aherne GW & Briggs R. (1989). The relevance of the presence of certain synthetic steroids in the aquatic environment. J Pharm Pharmacol., 41(10):735-736.

[5] Binh CT, Heuer H, Kaupenjohann M, Smalla K. (2008). Piggery manure used for soil fertilization is a reservoir for transferable antibiotic resistance plasmids. FEMS Microbiol Ecol., 66:25-37.

[6] Boxall ABA. (2004). The environmental side effects of medication. EMBO Rep., 5:1110–1116.

[7] Boxall ABA, Keller VD, Straub JO, Monteiro SC, Fussell R, Williams RJ. (2014). Exploiting monitoring data in environmental exposure modelling and risk assessment of pharmaceuticals. Environ Int., 73:176- 185.

[8] Brausch J, Connors K, Brooks B, Rand G. (2012). Human Pharmaceuticals in the Aquatic Environment: A Review of Recent Toxicological Studies and Considerations for Toxicity Testing, Reviews of Environmental Contamination and Toxicology, 218:1- 99.

[9] Brodin T, Fick J, Jonsson M, Klaminder J. (2013). Dilute Concentrations of a Psychiatric Drug Alter Behavior of Fish from Natural Populations. Science, 339:814.

[10] Brosche S & Backhaus T. (2010) Toxicity of five protein synthesis inhibiting antibiotics and their mixture to limnic bacterial communities. Aquatic toxicology, 99:457-465.

[11] Canesi L1, Lorusso LC, Ciacci C, Betti M, Regoli F, Poiana G, Gallo, G, Marcomini A. (2007). Effects of blood lipid lowering pharmaceuticals

(bezafibrate and gemfibrozil) on immune and digestive gland functions of the bivalve mollusc, Mytilus galloprovincialis. Chemosphere. 69(6):994-1002.

[12] Lettieri T. JRC (2104). Development of the 1st Watch List under the Environmental Quality Standards Directive. A Science and Policy Report by the Joint Research Centre (JRC), Luxembourg: Publications Office of the European Union.

[13] COM (2008) 666. Communication from the Commission to the European parliament, the Council, the European economic and social committee and the committee of the regions. Safe, Innovative and Accessible Medicines: a Renewed Vision for the Pharmaceutical Sector.

[14] Comber S, Gardner M, Jones V, Ellor B. (2014). Source apportionment of trace contaminants in urban sewer catchments. Environ Technol., 11:1-15

[15] De Lange HJ, Noordoven W, Murk AJ, Lürling M, Peeters ET, Dolliver H, Kumar K (2006). Behavioural responses of Gammarus pulex (Crustacea, Amphipoda) to low concentrations of pharmaceuticals. Aquat Toxicol., 78(3):209-216.

[16] EA (Environment Agency of England & Wales) (2000). Review of human pharmaceuticals in the environment, Technical Report P390. ISBN 1857054113. Bristol.

[17] EC (European Commission) (2014). Proposal for a regulation of the European Parliament and of the Council on veterinary medicinal products, COM (2014) 558 final 2014/0257 (COD) Brussels, 10.9.2014.

[18] Fick J, Söderström H, Lindberg RH, Phan C, Tysklind M, Larsson DG. (2009). Contamination of surface, ground, and drinking water from pharmaceutical production, Environmental Toxicology and Chemistry, 28(12): 2522–2527.

[19] Fick J, Lindberg RH, Parkkonen J, Arvidsson B, Tysklind M, Larsson DG. (2010). Therapeutic levels of levonorgestrel detected in blood plasma of fish: results from screening rainbow trout exposed to treated sewage effluents. Environ Sci Technol., 1,44(7):2661-2666.

[20] Fick J, Lindberg RH, Kay L, Brorstrom-Lunden E (2011). Results from the Swedish National Screening Programme 2010. Subreport 3. Pharmaceuticals. Sponsored by the Swedish Environmental Protection Agency.h

[21] Fong PP & Ford AT. (2014). The biological effects of antidepressants on the molluscs and crustaceans: a review. Aquatic Toxicology, 151:4-13

[22] Franzellitti S, Buratti S, Capolupo M, Haddad SP, Chambliss K, Brooks BW, Fabbri E. (2014). An exploratory investigation of various modes of action and potential adverse outcomes of fluoxetine in marine mussels, Aquatic Toxicology, 151: 1-134.

[23] Gardner M, Comber S, Scrimshaw MD, Cartmell E, Lester J, Ellor B. (2012). The significance of hazardous chemicals in wastewater treatment works effluents. Sci Total Environ., 437:363-372.

[24] Gardner M, Jones V, Comber S, Scrimshaw MD, Coello-Garcia T, Cartmell E, Lester J, Ellor B. (2013). Performance of UK wastewater treatment works with respect to trace contaminants. Sci Total Environ., 456-457:359-369.

[25] Gupta S (2007). Sulfamethazine uptake by plants from manure amended soil. J Environ Qual., 36(4):1224-1230.

[26] Halling-Sørensen B, Nors Nielsen S, Lanzky PF, Ingerslev F, Holten Lutzhøft HC, Jørgensen SE. (1998). Occurrence, fate and effects of pharmaceutical substances in the environment—a review. Chemosphere, 36:357-393.

[27] Hammesfahr U, Heuer H, Manzke B, Smalla K, Thiele-Bruhn S. (2008). Impact of the antibiotic sulfadiazine and pig manure on the microbial community structure in agricultural soils. Soil Biol Biochem., 40(7):1583– 1591.

[28] Han S, Choi K, Kim J, Ji K, Kim S, Ahn B, Yun J, Choi K, Khim JS, Zhang X, Giesy JP.(2010). Endocrine disruption and consequences of chronic exposure to ibuprofen in Japanese medaka (Oryzias latipes) and freshwater cladocerans Daphnia magna and Moina macrocopa. Aquat Toxicol., 1,98(3):256-64.

[29] Heberer T. (2002). Tracking persistent pharmaceutical residues from municipal sewage to drinking water, Journal of Hydrology, 266:175-189.

[30] Isidori M, Nardelli A, Pascarella L, Rubino M, Parrella A. (2007). Toxic and genotoxic impact of fibrates and their photoproducts on non-target organisms. Environ Int., 33(5):635- 641.

[31] Lumaret J-P, Errouissi F, Floate K, Römbke J, Wardhaugh K. (2012). A Review on the Toxicity

and Non-Target Effects of Macrocyclic Lactones in Terrestrial and Aquatic Environments Curr Pharm Biotechnol., 13(6): 1004–1060.

[32] Roy J. Pharmaceutical impurities—a mini-review, AAPS PharmSciTech 3 (2) (2002) (article 6 (http://www.aapspharmscitech.org)).

[33] ICH Harmonised Tripartite Guidelines: Impurities in New Drug Substances Q3A(R), 10 February 2003; Impurities in New Drug Products Q3B(R), November 2003; Impurities: Guideline for Residual Solvents, 24 December 1997; Stability Testing of New Drug Substances and Products Q1A(R2), November 2003 (http:// www.fda.gov/cder/guidance/ guidance.htm).

[34] Guidance for Industry, ANDAs: Impurities in Drug Products, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, August 2005 (http://www.fda.gov/cder/guidance/ 6423dftrev1.htm).

[35] Guidance for Industry, ANDAs: Impurities in Drug Substances, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, January 2005 (http://www.fda.gov/cder/ guidance/6422dft.htm)

[36] Chatwal GR. Pharmaceutical Inorganic chemistry, Vol.1. Himalaya, New Delhi, 1991.

[37] International Conferences on Harmonization, Draft Revised Guidance on Impurities in New Drug Substances. Q3A(R). Federal Register. 2000, 65 (140), 45085-45090.

[38] Basak AK, Raw AS, Al Hakim AH, Furness S, Samaan NI, Gill DS et al., Pharmaceutical impurities: Regulatory perspective for Abbreviated New Drug Applications, Advanced Drug Delivery Reviews, 2007, 59, 64-72